Nutra Pharma Corp. Reports 63% Revenue Decline in Q1 2026

Nutra Pharma Corp. reported its financial results for the first quarter of 2026, revealing a significant decline in revenue compared to the same period in 2025. For the three months ended March 31, 2026, the company generated net sales of $27,246, a decrease of approximately 63% from $73,974 in the prior year. The decline in revenue was primarily attributed to reduced sales to related parties, which fell from $36,420 to $20,968. The cost of sales also decreased, resulting in a gross profit of $18,975, down from $59,131 in the previous year.

The company's operating expenses for the first quarter of 2026 totaled $398,224, a slight decrease from $408,950 in the same period of 2025. Despite the reduction in expenses, Nutra Pharma reported a loss from operations of $379,249, compared to a loss of $349,819 in the prior year. The net loss for the quarter was $459,675, a significant improvement from the net loss of $1,404,923 reported in the first quarter of 2025. This improvement was largely due to a net gain on the settlement of debt amounting to $140,500, which was not present in the previous year.

In terms of operational developments, Nutra Pharma's total current assets increased to $499,424 as of March 31, 2026, up from $459,583 at the end of 2025. The company also reported a working capital deficit of $17,243,345 and a stockholders' deficit of $17,261,981. The total liabilities rose to $17,878,499, compared to $17,409,864 at the end of the previous fiscal year. The company continues to face challenges related to its accumulated deficit, which stood at $78,738,204 as of March 31, 2026.

Nutra Pharma's strategic focus remains on securing additional financing to support its operations and growth plans. The company has indicated that it does not have sufficient cash to sustain operations for the next twelve months and will rely on debt and equity funding to execute its business plan. The common stock is currently listed on the OTC Market Group's Expert Market, which limits its ability to raise capital. The company is exploring options to secure adequate funding through notes payable until its sales of pain products can sufficiently support operations.

Looking ahead, Nutra Pharma's management has expressed uncertainty regarding its ability to continue as a going concern, contingent upon securing additional financing and achieving profitable operations. The company is actively working to increase its market presence and product adoption rates, but it acknowledges the competitive environment and challenges in established markets. The outlook remains cautious as Nutra Pharma navigates its financial and operational hurdles while striving for growth in the biotechnology sector.